All the Active Ingredient Drugs
ACE Inhibitor. Ramipril 10 mg. CAPS: 10 mg.
Hypertens., CHF, reduct. mortality aft.
M.I: Initial. (for pts. not on diuretics):
2.5 mg 1 x dly. May incr. at intervals of
2-3 wks. up to 5 mg 1 x dly to max: 10
mg 1 x dly. Reduct. risk M.I, stroke or
CV death and/or need for
revascularizat: Initial: 2.5 mg 1 x dly.
Depend. On tolerabil. grad. incr. to
double after approx. 1 wk; aft. further
3 wks. incr. to 10 mg. Maint: 10 mg 1 x
dly. Pts already stabilized on lower
doses for other indicats., where
possible should be titrated to 10 mg 1
x dly.
Hypertens. congest. heart fail., reduct.
mortality aft. M.I. with left ventric.
dysfunct., reduce risk M.I., stroke, CV
death, need for revascularizat. in pts. over
55 yrs who have clinical evidence of CV
dis. (prev. M.I., unstable angina,
multivessel CABG or PTCA), stroke or
periph. vasc. dis. Also for reducing risk of
M.I., stroke, CV death or need for
revascularizat. procedures in diabet. pts of
55 yrs or more who have one or more of
the foll. clin. findings: hypertens. (systol.
pressure >160 mm Hg or diastol. pressure
>90 mm Hg); high total cholesterol (>5.2
mmol/L); low HDL (<0.9 mmol/L); current
smoker; known microalbuminur.; clin.
evidence of prev. vasc. dis., prevent.
progress. ren. fail. in pts. suffer. from
impair. ren. funct
ACE Inhibitor. Ramipril 1.25, 2.5, 5 mg. TABS: 28 x 1.25 mg, 2.5 mg, 5 mg.
Hypertens., CCF, reduct. of mortality
aft. M.I: Initial (for pt. not on diuretics):
2.5 mg 1 x dly. May incr. at intervals of
2-3 wks. up to 5 mg 1 x dly. to max. of
10 mg 1 x dly. Reducing risk of M.I.,
stroke or CV death and/or the need for
revascularization procedures: Initial:
2.5 mg 1 x dly. Depend. on tolerability,
dose should be gradually increas. to
double aft. about 1 wk. of tmt; then,
aft. a further 3 wks, increase to 10 mg.
Maint. dose: 10 mg 1 x dly. Pts already
stabilised on lower doses for other
indications where possible should be
titrated to 10 mg 1 x dly.
Hypertens. congest. heart fail., reduct.
mortality aft. M.I., reduce risk M.I., stroke,
CV death, need for revascularizat. in pts.
over 55 yrs who have clinical evidence of
CV dis. (prev. M.I., unstable angina,
multivessel CABG or PTCA), stroke or
periph. vasc. dis. Also for reducing risk of
M.I., stroke, CV death or need for
revascularizat. procedures in diabet. pts
of 55 yrs or more who have one or more
of the foll. clin. findings: hypertens.
(systol. pressure >160 mm Hg or diastol.
pressure >90 mm Hg); high total
cholesterol (>5.2 mmol/L); low HDL (<0.9
mmol/L); current smoker; known
microalbuminur.; clin. evidence of prev.
vasc. dis., prevent. progress. ren. fail. in
pts. with persist. proteinur. in excess of 1
g/day. Not suit. for tmt. hypertens. result.
from prim. hyperaldosteronism.
C/I: hypersens. histor. of angioed.
2nd and 3rd trimester of reg., hypotens.
Sig.bil. renal arter. stenos. See lit.
ACE Inhibitor, Thiazide. Hydrochlorothiazide 12.5 mg, 25 mg, Ramipril 2.5 mg, 5 mg. TABS: 28. Initial: 1 tab dly during or aft.
meals. May incr. at intervals of 2-3 wks.
if reqd. Max. dly dose: 10 mg
ramipril/50 mg HTCZ. See lit.
Essent. hypertens. when a comb. prep. is
indicated.
